UNSPSC 51152060: Inaperisone hydrochloride

This classification denotes a muscle relaxant with the molecular formula C16H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67D70I271P, chemically known as inaperisone hydrochloride, (+/-)-, but more generally known as inaperisone hydrochloride, which bears US NIH Compound Identifier 147524. European Medicines Agency schedules inaperisone hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08162MIG.

Most nations, for tariff purposes, schedule inaperisone hydrochloride under HS 29339990. SMILES: CCC1CCC(CC1)C(=O)C(C)CN2CCCC2.CL.

UNSPSC 51152060 Inaperisone hydrochloride is a Commodity code that nominally covers a specific pharmaceutical muscle relaxant, but recent state and local procurement activity under this code shows no alignment with that product scope. The single recent opportunity posted under the code—Seminole County, Florida's IFB for naloxone and drug deactivation systems—involves opioid-overdose reversal medication and harm-reduction equipment, not inaperisone. This mismatch suggests either a tagging error in the county's procurement system or a broader misclassification of pharmaceutical and medical supplies within the issuing body's UNSPSC framework. State and local governments typically source muscle relaxants through general pharmaceutical supply contracts or specialty medical distributors rather than through narrowly commodity-coded solicitations.

Seminole County's June 2026 IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement required electronic bid submission through the county's e-Procurement Portal, E-Verify compliance, drug-free workplace certification, and standard commercial insurance. The contract offered an initial two-year term with one-year renewal option and potential FEMA funding. Given the code's pharmaceutical focus and the sole recent opportunity's focus on overdose response, this code shows minimal current activity relevant to traditional inaperisone procurement. Business development teams evaluating this code should verify whether opportunities are being correctly classified before committing resources to tracking or pursuit.